CPSI Stockholder Trust
Patent Applications and Registrations
Patent applications and USPTO patent grants for CPSI Stockholder Trust.The latest application filed is for "compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor".
- CPSI Stockholder Trust - New York NY
| Patent | Date |
|---|---|
| Isoxazoline compounds having MIF antagonist activity Grant 8,552,040 - Al-Abed October 8, 2 | 2013-10-08 |
| Compounds, Compositions, Processes Of Making, And Methods Of Use Related To Inhibiting Macrophage Migration Inhibitory Factor App 20130225586 - Sielecki-Dzurdz; Thais ; et al. | 2013-08-29 |
| Use Of Isoxazoline Compounds And Compositions In Bladder Cancer App 20130196996 - Taylor, III; John Arthur ; et al. | 2013-08-01 |
| Chiral Synthesis Of Isoxazolines, Isoxazoline Compounds, And Uses Thereof App 20130172553 - Sielecki-Dzurdz; Thais ; et al. | 2013-07-04 |
| Isoxazoline Compounds In Type 2 Diabetes And Other Maladies App 20130123261 - Satoskar; Abhay ; et al. | 2013-05-16 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 